Showing results (181-190 of 221) with videos related to
Sort By:
Pageof 23
American Journal of Hematology|April 10, 2019
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk diseaseAndrés E Quesada, Mark J Routbort, Courtney D DiNardo, et al.Cancers|January 11, 2024
Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid TumorsLan Zheng, Rajyalakshmi Luthra, Hector A Alvarez, et al.British Journal of Haematology|March 30, 2019
Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatmentsBoyu Hu, Keyur P Patel, Hsiang-Chun Chen, et al.Blood Advances|February 7, 2020
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromesGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Christopher B Benton, et al.Blood Advances|April 22, 2021
Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclaxCurtis A Lachowiez, Sanam Loghavi, Ken Furudate, et al.JCO Precision Oncology|February 21, 2025
NTRK Fusion-Positive Thyroid Carcinoma: From Diagnosis to Targeted TherapyVicente R Marczyk, Sasan Fazeli, Ramona Dadu, et al.American Journal of Clinical Pathology|October 22, 2015
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencingSinchita Roy-Chowdhuri, Debora de Melo Gagliato, Mark J Routbort, et al.American Journal of Hematology|September 4, 2023
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variantsAlex Bataller, Sanam Loghavi, Yoheved Gerstein, et al.Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.Pageof 23